Focus Rheums| ACR Convergence 2024 Previews

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Progress Continues in Systemic Sclerosis

Daniel E. Furst, MD, Maureen D.Mayes, MD, MPH, Dinesh Khanna, MD,James R. Seibold, MD, Rajeev Saggar,MD, and Keith M. Sullivan, MD  |  Issue: March 2010  |  

Conclusions

Important advances have been gained in our understanding of the genetics, pathobiology and treatment of severe SSc. While SSc is often said to be the most fearsome of the autoimmune diseases, molecular targets for therapy have been defined and pilot trials of targeted therapies are underway. Convincing animal and human data demonstrate that the immune repertoire can be reset after hematopoietic stem cell transplantation leading to dramatic reversal of dermal fibrosis and stabilization to improvement of pulmonary disease. A pivotal National Institutes of Health–sponsored randomized trial comparing immunosuppression to immunoablative HCT is currently underway and patients are being recruited to the SCOT trial to test outcomes in these two promising treatments. Such trials will provide basic scientists with a better understanding of the regulatory pathways of SSc and rheumatologists with a context to weigh progress in the treatment of scleroderma.

Acknowledgments

This work was supported in part by NIH award AI-05419. The authors have nothing else to disclose.

ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Furst is professor in the division of rheumatology at UCLA; Dr. Mayes is professor in the division of rheumatology at the University of Texas in Houston; Dr. Khanna is assistant professor of rheumatology at UCLA; Dr. Seibold is professor of rheumatology at the University of Connecticut in Farmington; Dr. Saggar a clinical instructor in the division of pulmonary and critical care at UCLA; and Dr. Sullivan is the James B. Wyngaarden Professor of Medicine in the division of cellular therapy at Duke University Medical Center in Durham, N.C.

References

  1. Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes, MD. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three US cohorts. Arthritis Rheum. 2001; 44:1359-1362.
  2. Assassi S, Arnett FC, Reveille JC, Gourh P, Mayes MD. Clinical, immunological, and genetic features of familial systemic sclerosis. Arthritis Rheum. 2007: 56:2031-2037.
  3. Gorlova O, Weng S-F, Ying J, et al. Genome-wide association study of systemic sclerosis in a large U.S. cohort of over 1,500 cases. Arthritis Rheum. 2009; 60:S203 (abstract).
  4. Radstake TRDJ, Alizadeh BZ, Palomino-Morales R, et al. Genome-wide association scan in systemic sclerosis identified MHC region and two additional susceptibility loci on 2q32 and 7q32. Arthritis Rheum. 2009; 60:S473 (abstract).
  5. Arnett FC, Gourh P, Shete S, et al. Major Histocompatibility Complex (MHC) class II alleles, haplotypes, and epitopes which confer susceptibility or protection in the fibrosing autoimmune disease systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls. Ann Rheum Dis. 2009; Jul 12 (epub ahead of print).
  6. Scofield RH. Genetics of systemic lupus erythematosus and Sjogrens syndrome. Curr Opin Rheumatol. 2009; 21:448-453.
  7. Ji JD, Lee WJ, Kong KA, et al. Association of STAT4 polymorphism with rheumatoid arthritis and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep. 2010; 37:141-147.
  8. Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. 2007; 131:1917-1928.
  9. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:55-125.
  10. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54:555-566.
  11. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003;62:1088-1093.
  12. Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med. 1983; 75:65-74.
  13. D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428-440.
  14. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009;179:151-157.
  15. Mathai SC, Hummers LK, Champion HC, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009;60:569-577.
  16. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation. 2008;118:2183-2189.
  17. Proudman SM, Stevens WM, Sahhar J, Celermajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J. 2007;37:485-494.
  18. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997;28:434-442.
  19. Fisher MR, Mathai SC, Champion HC, et al. Clinical differences between idiopathic and scleroderma-related pulmonary hypertension. Arthritis Rheum. 2006;54:3043-3050.
  20. Sjogren RW. Gastrointestinal features of scleroderma. Curr Opin Rheumatol. 1996; 8(6):569-575.
  21. Kawaguchi Y, Nakamura Y, Matsumoto I, et al. Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotility. Ann Rheum Dis. 2009;68:710-714.
  22. Baron M, Hudson M, Steele R. Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database. J Rheumatol. 2009;36:2737-2743.
  23. Khanna D, Hays RD, Maranian P, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum. 2009;61:1257-1263.
  24. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of a one-year treatment with cyclophosphamide on outcomes at two years in scleroderma lung disease. Am J Resp Crit Care Med. 2007;176:1026-1034.
  25. Goh, N, Sujal SL, Desai R, et al. Interstitial lung disease in systemic sclerosis: A simple staging system. Am J Respir Crit Care Med. 2008;177:1248-1254.
  26. Denton CP, Merkel PA, Furst DE, et al. Recominant human anti-transforming growth factor beta 1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56:323-333.
  27. Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis. Rheumatology (Oxford). 2008; 47(Suppl 5):v10-v11.
  28. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985-3993.
  29. Atamas SP, White B. The role of chemokines in the pathogenesis of scleroderma. Curr Opin Rheumatol. 2003;15:772-777.
  30. Radstake TR, van Bon L, Broen J, et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One. 2009;4(6):e5903.
  31. Della Bella S, Molteni M, Mascagni B, et al. Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine. Clin Exp Rheumatol. 1997; 15:135-141.
  32. Ikehara S, Good Ra, Nakamura T, et al. Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Acad Sci USA. 1985;82:2483-2487.
  33. van Bekkum DW, Bohre EP, Houben PF, Knaan-Shanzer S. Regression of adjuvant-induced arthritis in rats following bone marrow transplantation. Proc Natl Acad Sci USA. 1989;86:1090-1094.
  34. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med. 2005;201:805-816.
  35. Sullivan KM, Muraro P, Tyndall A. Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. Biol Blood Marrow Transplant. 2010;16:S48-S56.
  36. Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood. 2007;110:1388-1396.

Related Articles